SBFM - Sunshine Biopharma nearly trebles market cap on anticancer effect of mRNA

Nano-cap stock, Sunshine Biopharma (SBFM +24.1%), is trading higher for the second straight session on Wednesday as the market continues to cheer the early results highlighting the anticancer effect of its mRNA molecules. More than 65.3 million Sunshine (NASDAQ:SBFM) shares have changed hands so far, compared to the 65-day average volume of ~3.8 million.  The shares more than doubled in value on Monday after the company said that the molecules “had little or no cytotoxic effects” against cancer cells grown in culture. With today’s gain, the little-known oncology-focused biotech has nearly trebled in value in just two days. With no drug candidates in clinical trials, Sunshine (SBFM) had struggled to maintain its share price, announcing multiple reverse stock splits over the past several years. In February, it completed its last reverse stock split, following the first two reverse stock splits in 2019 and 2020.

For further details see:

Sunshine Biopharma nearly trebles market cap on anticancer effect of mRNA